Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 1045-1055

  Park, Jin Hyun ^a   Han, Sae Won ^a,b   Oh, Do Youn ^a,b   Im, Seock Ah ^a,b   Jeong, Seung Yong ^a   Park, Kyu Joo ^a   Kim, Tae You ^a,b   Bang, Yung Jue ^a,b   Park, Jae Gahb ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

BRAF; Cetuximab; Colon cancer; EGFR intron 1 CA; KRAS; PTEN

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; MOLECULAR MARKER; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE 3 KINASE; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DNA SEQUENCE; DRUG ERUPTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SKIN TOXICITY; TREATMENT OUTCOME; WILD TYPE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRONS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 80054760645     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1586-z     Document Type: Article

References (31)

1. KY Chung J Shia NE Kemeny M Shah GK Schwartz A Tse A Hamilton D Pan D Schrag L Schwartz DS Klimstra D Fridman DP Kelsen LB Saltz 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 1803 1810 15677699 10.1200/JCO.2005.08.037 1:CAS:528:DC%2BD2MXjt1Ckuro%3D (Pubitemid 46211358)
2. F Cappuzzo G Finocchiaro E Rossi PA Janne C Carnaghi C Calandri K Bencardino C Ligorio F Ciardiello T Pressiani A Destro M Roncalli L Crino WA Franklin A Santoro M Varella-Garcia 2008 EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Ann Oncol 19 717 723 17974556 10.1093/annonc/mdm492 1:STN:280:DC%2BD1c3gsVKgsA%3D%3D (Pubitemid 351461042)
3. A Sartore-Bianchi M Moroni S Veronese C Carnaghi E Bajetta G Luppi A Sobrero C Barone S Cascinu G Colucci E Cortesi M Nichelatti M Gambacorta S Siena 2007 Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab J Clin Oncol 25 3238 3245 17664472 10.1200/JCO.2007.11.5956 1:CAS:528:DC%2BD2sXhtVWqs7vN (Pubitemid 47325607)
4. A Lievre J-B Bachet V Boige A Cayre D Le Corre E Buc M Ychou O Bouche B Landi C Louvet T Andre F Bibeau M-D Diebold P Rougier M Ducreux G Tomasic J-F Emile F Penault-Llorca P Laurent-Puig 2008 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 374 379 18202412 10.1200/JCO.2007.12.5906 1:CAS:528:DC%2BD1cXitVGntLc%3D (Pubitemid 351171687)
5. F Di Nicolantonio M Martini F Molinari A Sartore-Bianchi S Arena P Saletti S De Dosso L Mazzucchelli M Frattini S Siena A Bardelli 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705 5712 19001320 10.1200/JCO.2008.18.0786 1:CAS:528:DC%2BD1MXotFemsA%3D%3D
6. M Jhawer S Goel AJ Wilson C Montagna Y-H Ling D-S Byun S Nasser D Arango J Shin L Klampfer LH Augenlicht RP Soler JM Mariadason 2008 PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab Cancer Res 68 1953 1961 18339877 10.1158/0008-5472.CAN-07-5659 1:CAS:528:DC%2BD1cXjtFOhtro%3D (Pubitemid 351416582)
7. MM Weber C Fottner SB Liu MC Jung D Engelhardt GB Baretton 2002 Overexpression of the insulin-like growth factor I receptor in human colon carcinomas Cancer 95 2086 2095 12412161 10.1002/cncr.10945 1:CAS:528: DC%2BD38XptVKntLg%3D (Pubitemid 35253369)
8. A Hakam TJ Yeatman L Lu L Mora G Marcet SV Nicosia RC Karl D Coppola 1999 Expression of insulin-like growth factor-1 receptor in human colorectal cancer Hum Pathol 30 1128 1133 10534157 10.1016/S0046-8177(99)90027-8 1:CAS:528:DyaK1MXntVCmt7Y%3D (Pubitemid 29480878)
9. F Cappuzzo M Varella-Garcia G Finocchiaro M Skokan S Gajapathy C Carnaghi L Rimassa E Rossi C Ligorio L Di Tommaso AJ Holmes L Toschi G Tallini A Destro M Roncalli A Santoro PA Janne 2008 Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients Br J Cancer 99 83 89 18577988 10.1038/sj.bjc.6604439 1:CAS:528:DC%2BD1cXnvFeru7Y%3D (Pubitemid 351920237)
10. ML Amador D Oppenheimer S Perea A Maitra G Cusati C Iacobuzio-Donahue SD Baker R Ashfaq C Takimoto A Forastiere M Hidalgo 2004 An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors Cancer Res 64 9139 9143 15604284 10.1158/0008-5472.CAN-04- 1036 1:CAS:528:DC%2BD2cXhtVOmsb7O (Pubitemid 39665528)
11. F Loupakis L Pollina I Stasi A Ruzzo M Scartozzi D Santini G Masi F Graziano C Cremolini E Rulli E Canestrari N Funel G Schiavon I Petrini M Magnani G Tonini D Campani I Floriani S Cascinu A Falcone 2009 PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer J Clin Oncol 27 2622 2629 19398573 10.1200/JCO.2008.20.2796 1:CAS:528: DC%2BD1MXnslWit7o%3D
12. Kim SJ, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, Dewhirst MW, Vujaskovic Z, Kelley MJ (2009) Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol 27:91-97
13. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli L Bemis J Haney S Witta K Danenberg I Domenichini V Ludovini E Magrini V Gregorc C Doglioni A Sidoni M Tonato WA Franklin L Crino PA Bunn Jr M Varella-Garcia 2005 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 643 655 15870435 10.1093/jnci/dji112 1:CAS:528:DC%2BD2MXjvFymt70%3D (Pubitemid 40812628)
14. M Frattini D Balestra S Suardi M Oggionni P Alberici P Radice A Costa MG Daidone E Leo S Pilotti L Bertario MA Pierotti 2004 Different genetic features associated with colon and rectal carcinogenesis Clin Cancer Res 10 4015 4021 15217933 10.1158/1078-0432.CCR-04-0031 1:CAS:528:DC%2BD2cXltFWmtbs%3D (Pubitemid 38812476)
15. M Frattini C Ferrario P Bressan D Balestra L De Cecco P Mondellini I Bongarzone P Collini M Gariboldi S Pilotti MA Pierotti A Greco 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer Oncogene 23 7436 7440 15273715 10.1038/sj.onc.1207980 1:CAS:528:DC%2BD2cXnsleltL0%3D (Pubitemid 39382146)
16. M Frattini P Saletti E Romagnani V Martin F Molinari M Ghisletta A Camponovo L Etienne F Cavalli L Mazzucchelli 2007 PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients Br J Cancer 97 1139 1145 17940504 10.1038/sj.bjc.6604009 1:CAS:528:DC%2BD2sXhtFKktb7P (Pubitemid 47587019)
17. A Sartore-Bianchi M Martini F Molinari S Veronese M Nichelatti S Artale F Di Nicolantonio P Saletti S De Dosso L Mazzucchelli M Frattini S Siena A Bardelli 2009 PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 1851 1857 19223544 10.1158/0008-5472.CAN-08-2466 1:CAS:528:DC%2BD1MXisFSrt7Y%3D
18. A Lievre J Bachet D Le Corre V Boige B Landi J Emile J Cote G Tomasic C Penna M Ducreux P Rougier F Penault-Llorca P Laurent-Puig 2005 Kras mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992 3995 10.1158/0008-5472.CAN-06-0191
19. S Ogino K Nosho GJ Kirkner K Shima N Irahara S Kure AT Chan JA Engelman P Kraft LC Cantley EL Giovannucci CS Fuchs 2009 PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer J Clin Oncol 27 1477 1484 19237633 10.1200/JCO.2008.18.6544 1:CAS:528: DC%2BD1MXksF2hsL4%3D
20. A Lievre J-B Bachet D Le Corre V Boige B Landi J-F Emile J-F Cote G Tomasic C Penna M Ducreux P Rougier F Penault-Llorca P Laurent-Puig 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992 3995 16618717 10.1158/0008-5472.CAN-06-0191 1:CAS:528:DC%2BD28XjsFSlsb0%3D
21. H Lenz E Van-Cutsem S Khambata-Ford R Mayer P Gold P Stella B Mirtsching A Cohn A Pipas N Azarnia Z Tsuchihashi D Mauro E Rowinsky 2006 Multicenter phase II and translational study of cetuximab in Metastatic Colorectal Carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines J Clin Oncol 24 4914 4921 17050875 10.1200/JCO.2006.06.7595 1:CAS:528:DC%2BD28Xht1eiu73K (Pubitemid 46630920)
22. S Khambata-Ford CR Garrett NJ Meropol M Basik CT Harbison S Wu TW Wong X Huang CH Takimoto AK Godwin BR Tan SS Krishnamurthi HA Burris III EA Poplin M Hidalgo J Baselga EA Clark DJ Mauro 2007 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 3230 3237 17664471 10.1200/JCO.2006.10.5437 1:CAS:528:DC%2BD2sXhtVWqs7rF (Pubitemid 47325606)
23. SA Chrysogelos 1993 Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells Nucl Acids Res 21 5736 5741 8284222 10.1093/nar/21.24.5736 1:CAS:528:DyaK2cXhs1Sitbs%3D (Pubitemid 24003103)
24. Ruzzo A, Cremolini C, Loupakis F, Fornaro L, Santini D, Vincenzi B, Canestrari E, Magnani M, Falcone A, Graziano F (2009) Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients. J Clin Oncol (Meeting Abstracts) 27:4058
25. F Molinari V Martin P Saletti S De Dosso A Spitale A Camponovo A Bordoni S Crippa L Mazzucchelli M Frattini 2009 Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant Br J Cancer 100 1087 1094 19293803 10.1038/sj.bjc.6604848 1:CAS:528:DC%2BD1MXktVGktrY%3D
26. Abboud R, Pai R, Picus J, Hall-Daniels LE, Suresh R, Wang-Gillam A, Sorscher S, Tan BR (2010) Demographic factors on the incidence of KRAS mutation in colorectal cancers. J Clin Oncol 28 (suppl):e14040 (abstr)
27. H Rajagopalan A Bardelli C Lengauer KW Kinzler B Vogelstein VE Velculescu 2002 Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature 418 934 12198537 10.1038/418934a 1:CAS:528:DC%2BD38XmsFWksLs%3D (Pubitemid 34976022)
28. Cejas P, Lopez-Gomez M, Madero R, De Castro J, Casado E, Belda C, Larrauri J, Barriuso J, Gonzalez-Baron M, Feliu J (2009) Concordance of K-Ras status between colorectal cancer (CRC) primaries and related metastatic samples considering clinicopathological features. J Clin Oncol (Meeting Abstracts) 27:4053
29. S Artale A Sartore-Bianchi SM Veronese V Gambi CS Sarnataro M Gambacorta C Lauricella S Siena 2008 Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer J Clin Oncol 26 4217 4219 18757341 10.1200/JCO.2008.18.7286
30. D Cunningham Y Humblet S Siena D Khayat H Bleiberg A Santoro D Bets M Mueser A Harstrick C Verslype I Chau E Van Cutsem 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 15269313 10.1056/NEJMoa033025 1:CAS:528: DC%2BD2cXlvFGitbk%3D (Pubitemid 38944402)
31. J Tabernero E Van Cutsem E Diaz-Rubio A Cervantes Y Humblet T Andre JL Van Laethem P Soulie E Casado C Verslype JS Valera G Tortora F Ciardiello O Kisker A de Gramont 2007 Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 5225 5232 18024868 10.1200/JCO.2007.13.2183 1:CAS:528:DC%2BD2sXhsVKnsbzI (Pubitemid 350232254)